Imec and NeuroGyn AG are jointly developing an advanced neurostimulation device for disorders of the pelvic nerves

Imec and Neurogyn AG collaborate on advanced neurostimulation device for pelvic nerve disorders. The new solution aims at prolonging the lifetime of the device while lowering its cost, making it suitable at the point of need.

Imec, a globally leading research and innovation center for nanoelectronics and digital technologies, announces a collaboration with NeuroGyn AG, a Swiss medical technology company specializing in neurostimulation and surgical solutions for pelvic nerve disorders, to develop an implantable device of the next generation for peripheral nerve stimulation. The new solution leverages imec The Netherlands' expertise at the Holst Centre in wireless communication with very low power consumption and miniaturized power supply, aiming to extend the device's lifespan while reducing costs, making it suitable for use on the body. After the development phase, clinical validation is planned.

The pelvic nerves play an important role in bladder, sexual, and bowel functions, as well as in movements and sensations in the legs. Injuries or dysfunctions of the nerves in the pelvic organs can lead to disturbances in these areas, primarily urgency and overactivity, but also potential erectile dysfunction in men. Conservative treatments do not always provide sufficient relief and are often associated with debilitating side effects (leading to therapy discontinuation in 60% of cases). Neurostimulation, where electrodes deliver electrical impulses to nerves to alter their activity, can be an effective alternative treatment option for these patients. However, current commercial devices for this therapy are bulky, expensive, and have limited lifespan. The high costs of pelvic neuromodulation significantly hinder reimbursement by health insurance companies, especially for the treatment of functional bladder disorders, where the majority of patients are elderly or retirees; additionally, the treatment is not available for many patients and in many developing countries.

Imec researchers at the Holst Centre are now redesigning the neurostimulator, utilizing their advanced miniaturization technology in conjunction with the clinical expertise of NeuroGyn AG in this field. The project builds on imec's know-how in implantable solutions, such as wireless communication with very low power consumption and miniaturized power supplies, either near the skin surface or deeper inside the body. Imec already has experience in developing radio systems and chips that could facilitate recharging. A recharging function for the device would extend the lifespan of the implant. By reducing the battery and thus the implant size, the device is also intended to be minimally invasive and cost-effective. Imec's unique toolset for wireless communication and power supply for implants enables the development of customized solutions for medical devices. Considering the needs of users and recipients, the device can be adapted to facilitate implantation and alignment of the stimulation pathway.

"The new design aims to develop a smaller, state-of-the-art neurostimulator with advanced features that complement the patented surgical procedure of NeuroGyn AG. The project emphasizes our intention to make this technology accessible to everyone, including in developing countries, by designing the device affordably and enabling implantation by local physicians," said Prof. Dr. Marc Possover MD, founder and CSO of NeuroGyn AG.

"The collaboration with NeuroGyn AG marks the first highlight of our work on human implants and peripheral nerve stimulation technology, and is a great opportunity to develop a tailored device that considers the clinical expertise of the customer," said Zohaib Gulzar, Business Development Manager, Autonomous Therapeutics.